key: cord-0767218-03k6gzr2 authors: Adeyinka, Adebayo; Bailey, Keneisha; Pierre, Louisdon; Kondamudi, Noah title: COVID 19 infection: Pediatric perspectives date: 2021-01-29 journal: J Am Coll Emerg Physicians Open DOI: 10.1002/emp2.12375 sha: 549a34604a5fd57f6c14f877c6ccd5e4b4ae746e doc_id: 767218 cord_uid: 03k6gzr2 The coronavirus disease 2019 (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has rapidly spread across the globe, causing innumerable deaths and a massive economic catastrophe. Exposure to household members with confirmed COVID‐19 is the most common source of infection among children. Children are just as likely as adults to get infected with SARS‐CoV‐2. Most children are asymptomatic and when symptoms occur, they are usually mild. Infants <12 months old are at a higher risk for severe or critical disease. COVID‐19 is diagnosed the same way in pediatric population as adults by testing specimen obtained from upper respiratory tract for nucleic acid amplification test (NAAT) using reverse transcriptase viral polymerase chain reaction (RT‐PCR). The common laboratory findings in hospitalized patient include leukopenia, lymphopenia, and increased levels of inflammatory markers. Chest X‐ray findings are variable and computed tomography scans of the chest may show ground glass opacities similar to adults or non‐specific findings. Prevention is the primary intervention strategy. Recently the U.S. Food and Drug Administration (FDA) has provided emergency authorization of the Pfizer‐BioNTech COVID‐19 vaccine and many other vaccine candidates are in the investigational stage. There is limited data in children on the use of antivirals, hydroxychloroquine, azithromycin, monoclonal antibody, and convalescent plasma. Oxygen therapy is required in hypoxic children (saturation <92%). Similar to adults, other measures to maintain oxygenation such as high flow nasal cannula, CPAP, or ventilatory support may be needed. Ventilatory management strategies should include use of low tidal volumes (5–6 cc/kg), high positive expiratory pressure, adequate sedation, paralysis, and prone positioning. Recently, a new entity associated with COVID‐19 called multisystem inflammatory syndrome in children (MIS‐C) has emerged. Clinical, laboratory, and epidemiological criteria are the basis for this diagnosis. Management options include ICU admission, steroids, intravenous gamma globulin, aspirin, anakinra, and anticoagulants. Vasoactive‐inotropic score (VIS) is used to guide vasopressor support. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), now SARS-CoV-2 is reported to be ∼2%-3%. 3 Children account for 9%-12% of patients diagnosed with COVID-19 infection. 4 In general, 90% of children positive for SARS-CoV-2 are "asymptomatic" or have mild-to-moderate symptoms. In a review of 2572 pediatric cases, only 15 children needed intensive care with 3 reported deaths. 5 Another study of children admitted to PICUs in the United States and Canada showed that 18 (38%) of the 48 children hospitalized required invasive ventilation with 16 survivals and 2 deaths. 6 Severe illness may occur in children younger than 1 year of age and those with other comorbidities or underlying conditions. 7 The first confirmed pediatric case of severe acute respiratory syndrome (SARS-CoV-2) infection was in Shenzhen in January 2020. 8 By the end of January 2020, China reported 16 cases originating from an infected family member. The clinical presentation and epidemiological characteristics of press articles, and accepted-for-publication studies were also evaluated, given the current scarcity of evidence. Coronaviruses are zoonotic viruses that can cause disease in both mammals and birds. SARS-CoV-2 infection consists of 2 phases: infection and host cell response. The life cycle of the virus begins with the infection of the host cell, divided into 5 phases: attachment, penetration, biosynthesis, maturation, and release. The SARS-CoV-2 has four structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N). This is depicted in Figures 1 and 2. 11, 12 The virus binds to a receptor on the surface of the host cell (attachment) and enters the cell via endocytosis or fusion to the membrane (penetration). Once inside the cell, the virus enters the host cell nucleus via viral mRNA. The viral mRNA is used to make viral protein (biosynthesis). The newly produced viral particles are then released (maturation and release). 12 Transmembrane trimetric glycoprotein make up the spike projecting from the viral surface, thus determining the diversity of coronaviruses and host tropism. In the spike, there are 2 functional subunits: the S1 subunit controls the binding to the host cell receptor, and the S2 subunit is for the fusion with cellular membranes. 13 Angiotensin-converting enzyme 2 (ACE2) is the functional receptor for SARS-CoV. Based on structural and functional analysis, SARS-CoV-2 binds to ACE2 receptors. Once the SARS-CoV-2 binds to the ACE2 receptors, the spike protein undergoes protease cleavage. The cleavage occurs in a 2-step process. After the initial cleavage at the S1/S2 cleavage site, S1 and S2 subunits remain non-covalently bound, and the distal S1 subunit plays a part in the stabilization of the membrane-anchored S2 subunit at the prefusion state. The expression of angiotensin-converting enzyme 2 (ACE2) is very high in the following organs like lungs, heart, ileum, kidney, and bladder. 14 SARS-CoV-2 has a furin cleavage site ("RPPA" sequence) at the S1/S2 site. Even though the S1/S2 site is exposed to cleavage by other proteases such as transmembrane protease serine 2 (TMPRSS2) and cathepsin L, the ubiquitous expression of furin may explain the pathogenicity of SARS-CoV-2. 15 Children have milder symptoms of COVID-19 infection and are often asymptomatic compared to adults. Several proposed hypotheses explain this difference. The first hypothesis suggests that the expression level of ACE2 may differ between adults and children. One study showed that ACE2 receptors abundantly expressed on well-differentiated ciliated epithelial cells. 17 ACE2 expression on the epithelium of the alveolar cells may be lower in the pediatric population. The second hypothesis proposes that pediatric patients have a qualitatively different response to the SARS-CoV-2 virus relative to adults. By the processes of aging, continuous antigen stimulation and thymic involution will eventually lead to shifts in T cell subset distribution from naïve T cells to central memory T cells, effector T cells, and effector memory T cells. 18 The third hypothesis rests on the premise that the simultaneous presence of other viruses in the epithelial lining of the lungs and airways in young children causes the SARS-CoV-2 virus to compete with them limiting its growth and proliferation. 18 One or a combination of these mechanisms may explain why SARS-CoV-2 has less severity in the pediatric population. A better understanding of these mechanisms may aid in developing appropriate therapy. The case definition for pediatric COVID-19 has been variable in the literature. The Chinese Centers for Disease Control and Prevention reported that only 2% of the 72,314 reported cases occurred in children that were less than 19 years of age. 19 More recent data in the United States shows that children account for 9%-12% of patients diagnosed with COVID-19 infection (in general, 90% of children positive for SARS-CoV-2 are asymptomatic or have mild to moderate symptoms). 20 By mid-November 2020, the number of pediatric COVID-19 cases surpassed the 1 million mark. 21 It appears that COVID-19 occurs more often among the 12-to 17-year age group compared to the 5-to 11-year age group in the United States. 22 In a multicenter study of 48 children admitted with COVID-19 to PICUs in Canada and the United States, 40 patients (83%) had preexisting comorbidities and most (35; 73%) presented with respiratory symptoms. Eleven patients (38%) had a failure of 2 or more organs, and 1 patient (2%) required ECMO. 6 Most children are thought to be exposed to the virus from an adult at home. 29 Currently, no evidence exists of vertical transmission from mother to child. 30 Although children can transmit the virus to others, the transmission rate is unclear with younger children less likely to transmit compared to children >10 years old. 31 The incubation period is 2-14 days with a median of 6 days after exposure, similar to that in adults. 32 A large proportion of children with COVID-19 are asymptomatic. When symptomatic, manifestations include fever, nasal congestion/rhinorrhea, dyspnea, loss of sense of smell and taste, cough, sore throat, diarrhea, nausea/vomiting, fatigue, headache, myalgia, and poor feeding/poor appetite. 33 Unlike adults, children with COVID-19 may not always present with fever and cough. 34 In one pediatric case report, the only presenting symptom was diarrhea. 35 In another case series of 9 hospitalized infants in China with confirmed COVID-19, only 50% of them presented with fever. 36 The clinical course of SARS-CoV-2 based on >2000 cases in children described in China is shown in Table 1 . The CDC does not recommend the use of serum antigen tests for the diagnosis or management of acute infection in neonates. 43 In many asymptomatic or mildly symptomatic children, the labs may be normal. The most common laboratory abnormalities among hos-pitalized patients include leukopenia or leukocytosis, lymphopenia, elevated levels of alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase. Inflammatory markers like CRP, ESR, procalcitonin, D-dimer, and ferritin levels may also be increased, particularly in MIS-C. 44, 45 Elevated troponin in COVID 19 patients is associated with myocarditis and may be associated with poor prognosis. 46 Chest x-ray to detect lung involvement has low sensitivity, and CT chest should be considered when there is a respiratory compromise. Radiological findings in pediatric patients with COVID-19 are similar to those of adults, comprising of unilateral or bilateral infiltrates and some show ground-glass opacities, especially in the lower lobes. 47 Sonogram and CT scan of the chest may show nonspecific findings or ground glass appearance similar to adults. 48 Some patients have bilateral multi-lobular and subsegmental areas of atelectasis, and the number of involved lung segments correlates with disease severity. The opacifications tend to coalesce as the disease progresses. CT scan alone should not be used for the diagnosis of COVID-19 as it may not be a valuable screening tool for COVID- 19 . 49 According to Buda et al, the use of ultrasound is somewhat attractive because it is non-invasive, portable, and may be performed several times during the course of illness. The transthoracic lung ultrasound is generally used to detect pulmonary edema in patients with acute respiratory distress syndrome (ARDS) with a sensitivity and specificity of 0.78 to 0. 9. 50,51 However, in the COVID-19 pandemic, the use of ultrasound for the detection of viral pneumonia has gained significant popularity and may detect changes earlier than a routine chest X-ray. 52 Initial assessment should make the determination if the patient has a mild (not ill, minimal symptoms, no hypoxia), moderate (fever, significant myalgia, mild hypoxia >93% without shortness of breath) or severe illness (dyspnea, ill appearing, hypoxia <92%). Patients with mild symptoms can be managed at home with supportive care, such as antipyretics for fever maintenance of adequate hydration, appropriate isolation and education of caregivers regarding emergency warning signs. 53 Patients with moderate to severe symptoms should be hospitalized for specialized care. Most affected children are managed similar to adults. Therapies are still evolving, and there is no silver bullet at the present time. The best strategy at the current time is prevention through social distancing (6 feet apart), wearing of masks, and strict hand hygiene. 20 The American Academy of Pediatrics recommends that children older than 2 years should wear cloth face coverings, especially when social distancing is not possible. 54 In the hospital setting, strict infection control should be practiced including frequent hand washing, appropriate donning and doffing of personal protective equipment (PPE) and special precautions during high risk (eg, aerosolizing) procedures. Eye protection with goggles or face shields is recommended in the health care settings. 55 Early testing and isolation of those with positive tests combined with contact tracing can further help reduce the transmission of this virus. There is currently no evidence to support the use of prophylactic antibiotics to prevent COVID-19 infection, although this may be considered for the initial management of patients presenting with shock for presumed bacterial sepsis. The RECOVERY trial in United Kingdom showed reduced mortality at 28 days for COVID-19-affected hospitalized adult patients who were on supplemental oxygen or on mechanical ventilation. In patients hospitalized with COVID-19, the administration of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. 56 At present, no conclusive evidence exists about the use of steroids in children, although there may be benefit in patients that require mechanical ventilation. 57 Previous experience with the use of steroids to treat SARS-CoV and MERS-CoV showed increased mortality, higher secondary infections, and occurrence of complications such as psychosis, hyperglycemia, delayed viral clearance, and enhanced risk of mutation of the pathogen. 58 If steroids are used, it is prudent to use at minimal effective doses for the shortest time. 58 The use of anticoagulation therapy is recommended in patients with early-stage COVID-19, especially when the D-dimer value is 4 times higher. The presence of inflammation and other disease-related factors can cause overactivation of coagulation, thereby increasing the risk of ischemic events and disseminated intravascular coagulation (DIC). 59 The 10-day course. 61 Another investigational drug, lopinavir/ritonavir, an antiretroviral drug combination that inhibits protease, has shown some efficacy in its ability to reduce the viral load in COVID-19 patients. 62 The NIH treatment guideline panel has recommended against the use of this drug. Other drugs not recommended by the panel include chloroquine and hydrochloroquine with or without azithromycin, ivermectin, and other HIV protease inhibitors. On November 21, 2020, the FDA issued emergency use authorization for monoclonal antibodies, casirivimab and imdevimab, to be administered together, for the treatment of mild to moderate COVID-19 in adults and children <12 years and weighing at least 40 kg, who are at high risk for progressing to severe COVID-19 disease. 63 ,64 The use of passive immunotherapy is another option. Convalescent plasma has shown potential benefits in adults with SARS-CoV-2 but has theoretical risks. The mechanism of action of convalescent plasma is via neutralizing antibodies binding to the virus, rendering it inert. 65 The initial series of convalescent plasma administration in adults with COVID-19 showed potential benefits without apparent side effects. 66 In a recent case report, 4 pediatric patients with SARS-CoV-2 and acute respiratory distress syndrome were given convalescent plasma. The administration of convalescent plasma was not associated with antibody-dependent enhancement (ADE) and did not dampen the endogenous antibody response. 67 Oxygen therapy is beneficial for patients with hypoxia to keep oxy- The CDC case definition for MIS-C includes the following: To establish the diagnosis of MIS-C, the following tests are recom- Pediatric patients are broadly classified into 3 groups based on disease severity. Mild disease presents with no requirement for vasoac-F I G U R E 1 COVID-19 viral structure. Diagram of the structure of the COVID-19 virus. 11 Adapted from structure and genome of SARS-CoV-2 (COVID-19) with diagram tive support, minimal to no respiratory support, and minimal organ injury. The moderate category counts a vasoactive-inotropic score (VIS) ≤10, significant supplemental oxygen requirement, mild or isolated organ injury. Severely ill patients have a VIS >10, non-invasive or invasive ventilatory support, moderate or severe organ injury, including moderate to severe ventricular dysfunction. The VIS was derived from the previously described inotropic score which quantifies the amount of cardiovascular support required by pediatric patients postoperatively and includes dopamine, dobutamine, epinephrine, milrinone, vasopressin, and norepinephrine. The VIS is calculated using the formula: dopamine dose (μg/kg/min) + dobutamine (μg/kg/min) + 100 × epinephrine dose (μg/kg/min + 100 × norepinephrine dose + 10 × milrinone (μg/kg/min). 74 The American Academy of Pediatrics strongly advocates that the goal should be to have students physically present in school and administrators take all measures to mitigate the risk of COVID-19 spread through physical distancing, wearing masks, and thorough disinfection. 78 SAR-CoV2 or COVID-19 is an infectious disease that has quickly emerged as a global pandemic making an unprecedented and devastating social and economic impact. Affected children do not appear to have the same degree of severity of illness as seen in adults. MIS-C is a new entity that is uniquely seen in pediatric patients infected with COVID-19 and usually requires hospitalization to an intensive care unit and managed by a multidisciplinary team of specialists. There is a need for more research to understand the disease in children and develop optimal therapies and effective vaccines. Vaccines against have been developed by several pharmaceutical companies and implementation of vaccination in adults will start shortly. As of December 11, 2020, the U.S. Food and Drug Administration has issued the first emergency use authorization for a vaccine for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status Three emerging coronaviruses in two decades Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission CDC. COVID-19 Cases, Deaths, and Trends in the US | CDC COVID Data Tracker Disease 2019 in Children -United States Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and canadian pediatric intensive care units Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou Novel coronavirus disease (COVID-19) in children Childhood multisystem inflammatory syndrome -a new challenge in the pandemic Molecular immune pathogenesis and diagnosis of COVID-19 COVID-19) with diagram. Microbe Notes COVID-19 pathophysiology: a review The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Virus clearance through apoptosis-dependent phagocytosis of influenza A virus-infected cells by macrophages ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Centers for Disease Control and Prevention Pediatric COVID-19 cases surpass 'tragic' 1 million mark. AAP News COVID-19 trends among school-aged children -United States Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 -COVID-NET, 14 states COVID-19-Associated multisystem inflammatory syndrome in children -United States Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records Coronavirus disease 2019 (COVID-19) in Italy Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid COVID-19 in children and the dynamics of infection in families 2019-nCoV transmission through the ocular surface must not be ignored On the effect of age on the transmission of SARS-CoV-2 in households, schools, and the community The Incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application | annals of internal medicine SARS-CoV-2 infection in children Epidemiology of COVID-19 among children in China Clinical features of pediatric patients with COVID-19: a report of two family cluster cases. World J Pediatr WJP Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China | Global Health | JAMA | JAMA Network COVID-19 diagnosis and management: a comprehensive review Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak -United States Detection of SARS-CoV-2 in different types of clinical specimens Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases SARS-COV-2 infection in children and newborns: a systematic review COVID-19). Centers for Disease Control and Prevention COVID-19 in children, pregnancy and neonates: a review of epidemiologic and clinical features Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults Coronavirus disease 2019 (COVID-19) in children: a systematic review of imaging findings The value of chest CT as a COVID-19 screening tool in children Lung ultrasound in the diagnosis of COVID-19 infection-a case series and review of the literature Ultrasound patterns of pulmonary edema Lung ultrasound in children with respiratory tract infections: viral, bacterial or COVID-19? A Narrative Review Centers for Disease Control and Prevention Examining the need for eye protection for coronavirus disease 2019 (COVID-19) prevention in the community Dexamethasone in hospitalized patients with Covid-19 -preliminary report COVID-19 Treatment Guidelines Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia Hypothesis for potential pathogenesis of SARS-CoV-2 infectiona review of immune changes in patients with viral pneumonia COVID-19 Treatment Guidelines Remdesivir as a possible therapeutic option for the COVID-19 Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR Statement on Casirivimab Plus Imdevimab EUA. COVID-19 Treatment Guidelines Deployment of convalescent plasma for the prevention and treatment of COVID-19 Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome Prone position for acute respiratory distress syndrome. a systematic review and meta-analysis Preparing for the Most Critically Ill Patients With COVID-19: The Potential Role of Extracorporeal Membrane Oxygenation | Critical Care Medicine | JAMA | JAMA Network Clinical management of COVID-19 Pediatric Critical Care Medicine What can we expect from first-generation COVID-19 vaccines? Inflammatory Syndrome in Children (MIS-C). Centers for Disease Control and Prevention Validation of the vasoactive-inotropic score in pediatric sepsis Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance American college of rheumatology. clinical guidance for pediatric patients with multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 and hyperinflammation in COVID-19 COVID-19 Interim Guidance: Return to Sports. Accessed Planning Considerations: Guidance for School Reentry The authors wish to acknowledge the contribution of Clarisse Pierre and Dorisse Pierre for the diagram in Figure 1 (COVID-19 viral structure) and Figure 2 (COVID-19 transcription and replication). The authors declare no conflicts of interest. Adebayo Adeyinka MD https://orcid.org/0000-0002-0548-1478